{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:38:00Z","timestamp":1792798680934,"version":"4.5.0"},"reference-count":30,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T00:00:00Z","timestamp":1690416000000},"content-version":"unspecified","delay-in-days":26,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries Ltd","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NIH"},{"name":"US WorldMeds LLC","id":[{"id":"https:\/\/ror.org\/031sv1179","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100014546","name":"New York State Psychiatric Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014546","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000058","name":"Substance Abuse and Mental Health Services Administration","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000058","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100018529","name":"Alkermes plc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100018529","id-type":"DOI","asserted-by":"crossref"}]},{"name":"US World Meds, Alkermes plc"},{"DOI":"10.13039\/100007062","name":"Major League Baseball","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Washington University Institute of Clinical and Translational Sciences","award":["UL1 TR002345"],"award-info":[{"award-number":["UL1 TR002345"]}]},{"name":"Merative Corporation in the United States"},{"name":"Program of Washington"},{"name":"National Center for Advancing Translational Sciences of the National Institutes of Health","id":[{"id":"https:\/\/ror.org\/04pw6fb54","id-type":"ROR","asserted-by":"crossref"}]},{"name":"John Sahrmann MS"},{"name":"Center for Administrative Data Research (CADR) of Washington University","id":[{"id":"https:\/\/ror.org\/01yc7t268","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Center for Administrative Data Research"},{"name":"Dustin Stwalley MA"},{"DOI":"10.13039\/100007268","name":"Washington University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007268","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014848","name":"Arnold Ventures LLC","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014848","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Matt Keller MS"},{"name":"Saint Louis University Research Institute","award":["R21 DA044744"],"award-info":[{"award-number":["R21 DA044744"]}]},{"name":"Saint Louis University Research Institute","award":["T32 DA015035"],"award-info":[{"award-number":["T32 DA015035"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Ment Health"],"accepted":{"date-parts":[[2023,7,12]]},"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Attention-deficit and hyperactivity disorder (ADHD) is frequently diagnosed in patients with substance use disorders (SUDs), including opioids. There remains concern about the safety and efficacy of prescription amphetamines (PAs) and their impact on effectiveness of opioid use disorder (OUD) treatment with buprenorphine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To assess the effect of PAs on OUD buprenorphine treatment retention and\/or SUD-related emergency admission or drug-related poisonings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We used a retrospective cohort design with a secondary analysis of data from Merative MarketScan Commercial and Multi-State Medicaid Databases from 1 January 2006 to 31 December 2016. Individuals included were aged 12\u201364 years, had an OUD diagnosis and were prescribed buprenorphine. Our analysis used multivariable Cox regression to evaluate the relationship between PA receipt and time to buprenorphine discontinuation. The second part focused on subsamples of buprenorphine initiators who had either (1) any SUD-related emergency admissions or (2) drug-related poisoning. These outcomes were modelled as a function of PA exposure using conditional logistic regression models as part of a within-person, case-crossover design.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>Our sample had 90\u2009269 patients with OUD (mean age 34.2 years (SD=11.3)) who initiated buprenorphine. Being prescribed a PA was associated with improved buprenorphine retention among individuals both with (adjusted HR (aHR) 0.91 (95% CI 0.86 to 0.97)) and without a concurrent psychostimulant use disorder (PSUD) (aHR 0.92 (95% CI 0.90 to 0.93)).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>PA use was associated with improved buprenorphine retention in people with OUD with and without co-occurring PSUD. The risks of acute SUD-related events and drug-related poisonings associated with PA use did not differ when comparing PA-using days with days without PA use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical implications<\/jats:title>\n                    <jats:p>Patients with OUD on buprenorphine should receive treatment with a PA when indicated.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjment-2023-300728","type":"journal-article","created":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T11:30:30Z","timestamp":1690457430000},"page":"e300728","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":18,"title":["Prescription amphetamines in people with opioid use disorder and co-occurring psychostimulant use disorder initiating buprenorphine: an analysis of treatment retention and overdose risk"],"prefix":"10.1136","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6040-7708","authenticated-orcid":false,"given":"Vitor","family":"Tardelli","sequence":"first","affiliation":[{"name":"Department of Psychiatry, Universidade Federal de Sao Paulo, Sao Paulo, Brazil"},{"name":"Translational Addictions Research Lab, Centre for Addiction and Mental Health, Department of Psychiatr, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin Y","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Bisaga","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, College of Physicians and Surgeons of Columbia University, New York City, New York, USA"},{"name":"Division of Substance Use Disorders, New York State Psychiatric Institute, New York City, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances R","family":"Levin","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, College of Physicians and Surgeons of Columbia University, New York City, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thiago M","family":"Fidalgo","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Universidade Federal de Sao Paulo, Sao Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A","family":"Grucza","sequence":"additional","affiliation":[{"name":"Department of Family and Community Medicine, Saint Louis University, St. Louis, Missouri, USA"},{"name":"Department of Health and Outcomes Research, Saint Louis University, St. Louis, Missouri, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,7,27]]},"reference":[{"key":"2025082623363208000_26.1.e300728.1","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1001\/jamapsychiatry.2021.2588","article-title":"Methamphetamine use, methamphetamine use disorder, and associated overdose deaths among US adults","volume":"78","author":"Han","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"2025082623363208000_26.1.e300728.2","doi-asserted-by":"crossref","first-page":"202","DOI":"10.15585\/mmwr.mm7006a4","article-title":"Trends and geographic patterns in drug and synthetic opioid overdose deaths - United States, 2013-2019","volume":"70","author":"Mattson","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2025082623363208000_26.1.e300728.3","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1177\/07067437221125302","article-title":"Marked increase in amphetamine-related emergency Department visits and inpatient admissions in Toronto, Canada, 2014\u20132021","volume":"68","author":"Tardelli","year":"2023","journal-title":"Can J Psychiatry"},{"key":"2025082623363208000_26.1.e300728.4","doi-asserted-by":"crossref","first-page":"108416","DOI":"10.1016\/j.drugalcdep.2020.108416","article-title":"Fentanyl and fentanyl analogs in the illicit stimulant supply: results from U.S. drug seizure data, 2011-2016","volume":"218","author":"Park","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"2025082623363208000_26.1.e300728.5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/nyas.14688","article-title":"Methamphetamine use in the United States: Epidemiological update and implications for prevention, treatment, and harm reduction","volume":"1508","author":"Jones","year":"2022","journal-title":"Ann N Y Acad Sci"},{"key":"2025082623363208000_26.1.e300728.6","article-title":"Concurrent use of opioids and stimulants and risk of fatal overdose: A cohort study","volume":"22","author":"Palis","year":"2084","journal-title":"BMC Public Health"},{"key":"2025082623363208000_26.1.e300728.7","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/ajr.12331","article-title":"Ice and the outback: patterns and prevalence of methamphetamine use in rural Australia","volume":"25","author":"Roche","year":"2017","journal-title":"Aust J Rural Health"},{"key":"2025082623363208000_26.1.e300728.8","doi-asserted-by":"crossref","first-page":"244","DOI":"10.12968\/jpar.2017.9.6.244","article-title":"Methamphetamine use and emergency services in Australia: a Scoping review","volume":"9","author":"Ross","year":"2017","journal-title":"Journal of Paramedic Practice"},{"key":"2025082623363208000_26.1.e300728.9","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12873-022-00573-0","article-title":"Emergency Department visits and trends related to cocaine, Psychostimulants, and opioids in the United States, 2008-2018","volume":"22","author":"Suen","year":"2022","journal-title":"BMC Emerg Med"},{"key":"2025082623363208000_26.1.e300728.10","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1177\/10600280221141065","article-title":"Gaps in evidence-based treatment of concurrent attention deficit hyperactivity disorder and opioid use disorder: A Scoping review","volume":"57","author":"Ramey","year":"2023","journal-title":"Ann Pharmacother"},{"key":"2025082623363208000_26.1.e300728.11","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-020-05563-3"},{"key":"2025082623363208000_26.1.e300728.12","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.20m13598","article-title":"Pharmacotherapy for attention-deficit\/hyperactivity disorder and retention in outpatient substance use disorder treatment: A retrospective cohort study","volume":"82","author":"Kast","year":"2021","journal-title":"J Clin Psychiatry"},{"key":"2025082623363208000_26.1.e300728.13","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1001\/jamapsychiatry.2022.3788","article-title":"Association of pharmacological treatments and hospitalization and death in individuals with amphetamine use disorders in a Swedish nationwide cohort of 13 965 patients","volume":"80","author":"Heikkinen","year":"2023","journal-title":"JAMA Psychiatry"},{"key":"2025082623363208000_26.1.e300728.14","article-title":"Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults","volume":"8","author":"Castells","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2025082623363208000_26.1.e300728.15","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2008-3138"},{"key":"2025082623363208000_26.1.e300728.16","doi-asserted-by":"publisher","DOI":"10.2165\/11599630-000000000-00000"},{"key":"2025082623363208000_26.1.e300728.17","doi-asserted-by":"publisher","DOI":"10.1177\/1087054712468486"},{"key":"2025082623363208000_26.1.e300728.18","doi-asserted-by":"crossref","unstructured":"P\u00e9rez-Ma\u00f1\u00e1 C , Castells X , Torrens M , et al . Efficacy of Psychostimulant drugs for amphetamine abuse or dependence. Cochrane Database Syst Rev 2013:CD009695. doi:10.1002\/14651858.CD009695.pub2","DOI":"10.1002\/14651858.CD009695.pub2"},{"key":"2025082623363208000_26.1.e300728.19","article-title":"Psychostimulant drugs for cocaine dependence","volume":"9","author":"Castells","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"2025082623363208000_26.1.e300728.20","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.11634","article-title":"Analysis of stimulant prescriptions and drug-related poisoning risk among persons receiving buprenorphine treatment for opioid use disorder","volume":"5","author":"Mintz","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2025082623363208000_26.1.e300728.21","doi-asserted-by":"crossref","first-page":"108886","DOI":"10.1016\/j.drugalcdep.2021.108886","article-title":"An examination between treatment type and treatment retention in persons with opioid and Co-occurring alcohol use disorders","volume":"226","author":"Mintz","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"2025082623363208000_26.1.e300728.22","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.m772","article-title":"Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: population based retrospective cohort study","volume":"368","author":"Pearce","year":"2020","journal-title":"BMJ"},{"key":"2025082623363208000_26.1.e300728.23","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3434"},{"key":"2025082623363208000_26.1.e300728.24","doi-asserted-by":"crossref","unstructured":"Dong H , Stringfellow EJ , Russell WA , et al . Impact of alternative ways to Operationalize buprenorphine treatment duration on understanding continuity of care for opioid use disorder. Int J Ment Health Addiction 2022:1\u20136. doi:10.1007\/s11469-022-00985-w","DOI":"10.1007\/s11469-022-00985-w"},{"key":"2025082623363208000_26.1.e300728.25","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jsat.2019.07.010","article-title":"Prescribing decisions at buprenorphine treatment initiation: do they matter for treatment discontinuation and adverse opioid-related events?","volume":"105","author":"Meinhofer","year":"2019","journal-title":"J Subst Abuse Treat"},{"key":"2025082623363208000_26.1.e300728.26","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1176\/appi.ajp.2019.19060612","article-title":"Acute care, prescription opioid use, and overdose following discontinuation of long-term buprenorphine treatment for opioid use disorder","volume":"177","author":"Williams","year":"2020","journal-title":"Am J Psychiatry"},{"key":"2025082623363208000_26.1.e300728.27","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1176\/appi.ajp.2017.16060686","article-title":"ADHD medication and substance-related problems","volume":"174","author":"Quinn","year":"2017","journal-title":"Am J Psychiatry"},{"key":"2025082623363208000_26.1.e300728.28","unstructured":"Levin FR , Mariani JJ . Co-occurring addictive disorder and attention deficit\/hyperactivity disorder. In: Miller S , Fiellin D , Rosenthal R , et al , eds. ASAM Essentials of Addiction Medicine. 2019: 1418\u201367."},{"key":"2025082623363208000_26.1.e300728.29","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1001\/jamapsychiatry.2021.0976","article-title":"Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence: A systematic review and meta-analysis","volume":"78","author":"Santo","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"2025082623363208000_26.1.e300728.30","doi-asserted-by":"crossref","first-page":"109551","DOI":"10.1016\/j.drugalcdep.2022.109551","article-title":"Prevalence of mental disorders among people with opioid use disorder: A systematic review and meta-analysis","volume":"238","author":"Santo","year":"2022","journal-title":"Drug Alcohol Depend"}],"container-title":["BMJ Mental Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjment-2023-300728","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T06:36:46Z","timestamp":1756276606000},"score":1,"resource":{"primary":{"URL":"https:\/\/mentalhealth.bmj.com\/lookup\/doi\/10.1136\/bmjment-2023-300728"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,7,27]]},"published-print":{"date-parts":[[2023,7]]}},"alternative-id":["10.1136\/bmjment-2023-300728"],"URL":"https:\/\/doi.org\/10.1136\/bmjment-2023-300728","relation":{},"ISSN":["2755-9734"],"issn-type":[{"value":"2755-9734","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7]]}}}